| __timestamp | Agios Pharmaceuticals, Inc. | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 25434000 |
| Thursday, January 1, 2015 | 141827000 | 23783000 |
| Friday, January 1, 2016 | 220163000 | 29763000 |
| Sunday, January 1, 2017 | 292681000 | 12065000 |
| Monday, January 1, 2018 | 1397000 | 5508000 |
| Tuesday, January 1, 2019 | 1317000 | 75173000 |
| Wednesday, January 1, 2020 | 2805000 | 81497000 |
| Friday, January 1, 2021 | 18777000 | 85731000 |
| Saturday, January 1, 2022 | 1704000 | 63572000 |
| Sunday, January 1, 2023 | 9504000 | 54922000 |
| Monday, January 1, 2024 | 4165000 | 41070000 |
Unleashing insights
In the competitive world of biotechnology, cost efficiency can be a decisive factor for success. This analysis compares the cost of revenue efficiency between Mesoblast Limited and Agios Pharmaceuticals, Inc. over a decade, from 2014 to 2023. Mesoblast Limited has shown a consistent increase in cost efficiency, peaking in 2021 with a 237% rise from its 2014 figures. In contrast, Agios Pharmaceuticals experienced a dramatic fluctuation, with a notable peak in 2017, followed by a sharp decline in subsequent years. By 2023, Agios's cost of revenue was approximately 90% lower than its 2017 peak. This data highlights the contrasting financial strategies and market conditions faced by these companies. As the biotech industry continues to evolve, understanding these trends is crucial for investors and stakeholders aiming to make informed decisions.
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Mesoblast Limited
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Mesoblast Limited's Expenses
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Mesoblast Limited's Expenses
Cost of Revenue Comparison: Alkermes plc vs Mesoblast Limited
Comparing Cost of Revenue Efficiency: Bausch Health Companies Inc. vs Mesoblast Limited
Mesoblast Limited vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs MiMedx Group, Inc.
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.